Abcuro, Inc.

NEWS

A human hand showing dollar golden coins in the jar with a colored background. Collage Art of finance

Funding

Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion body myositis through clinical trials. Now, Abcuro is eyeing a regulatory submission and potential launch.

February 12, 2025

1 min read

Dan Samorodnitsky

IN THE PRESS

Press Releases

Abcuro Appoints George Eldridge as Chief Financial Officer

August 18, 2025

3 min read

Press Releases

Abcuro Appoints Courtney Cupples as Chief Commercial Officer

June 9, 2025

3 min read

Press Releases

Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting

March 11, 2025

2 min read

Press Releases

Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis

February 12, 2025

3 min read

Press Releases

Abcuro Announces Participation in Upcoming Investor Conferences

November 11, 2024

1 min read

Drug Development

Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis

June 25, 2024

3 min read

Business

Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors

December 6, 2023

2 min read

Drug Development

Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis

November 13, 2023

3 min read

Genetown

Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline

August 17, 2023

4 min read

Drug Development

Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

May 31, 2023

4 min read

JOBS